Interview

CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT 5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion 3:52
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney • 24 Feb 2023
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL 3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Shah • 15 Feb 2023
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL 3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma 2:47
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Sergio Giralt • 17 Feb 2023
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML 3:48
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML
Swati Naik • 20 Feb 2023
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers 0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
CAR-T therapy in acute and chronic leukemias: current applications and future outlooks 8:25
CAR-T therapy in acute and chronic leukemias: current applications and future outlooks
John Gribben • 10 Feb 2023
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA 1:05
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA
Hermann Einsele • 10 Feb 2023
Exploring the potential role of CD7-targeting CAR-T cells in T-ALL 2:21
Exploring the potential role of CD7-targeting CAR-T cells in T-ALL
Maksim Mamonkin • 10 Feb 2023
The importance of managing hematologic toxicity associated with CAR-T therapy 2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells 2:15
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner • 10 Feb 2023
Rapid CAR-T manufacturing and challenges in this space 1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells 1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy 5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL 1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam • 12 Dec 2022
The content of VJRegenMed is intended for healthcare professionals